Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & H...
Guardado en:
Autores principales: | Zhdanov K, Isakov V, Burnevich E, Kizhlo S, Bakulin I, Pokrovsky V, Liang L, Hwang P, Talwani R, Haber BA, Robertson MN |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6c4a393d1b8042dd92afc7b5cc393396 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
por: Sulejmani N, et al.
Publicado: (2018) -
Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
por: Page K, et al.
Publicado: (2019) -
Novel biomarkers assist in detection of liver fibrosis in HCV patients
por: Tamer A. Addissouky, et al.
Publicado: (2021) -
Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Atsushi Hosui, et al.
Publicado: (2021) -
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan SV, et al.
Publicado: (2015)